“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Sunday, August 31, 2025

Collegium Pharmaceutical


Collegium Pharmaceutical products


H

  • HLD200 (evening-dosed methylphenidate ER capsules)

    • Indication: treatment of attention-deficit/hyperactivity disorder (ADHD) in children (under development in clinical trials)

N

  • Nucynta® — tapentadol (IR)

    • Indication: management of acute pain severe enough to require an opioid when alternatives are inadequate

  • Nucynta® ER — tapentadol (extended-release)

    • Indication: management of severe chronic pain in patients requiring around-the-clock opioid therapy for whom alternative treatments are inadequate

  • Naldemedine (Symproic®)

    • Indication: opioid-induced constipation (OIC) in adults with chronic non-cancer pain

X

  • Xtampza® ER — oxycodone extended-release

    • Indication: severe chronic pain requiring long-term, around-the-clock opioid treatment, with an abuse-deterrent formulation

J

  • Jornay® PM — methylphenidate extended-release capsules

    • Indication: ADHD in patients aged 6 and older; designed for evening dosing to provide therapeutic effect the next morning




on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)